<FORM>
Guidance         for   Industry
 Distributing Scientific and Medical
 Publications on Risk Information for
  Approved   Prescription Drugs and
Biological Productsâ€”Recommended
              Practices
</FORM>
<TITLE>
DRAFT GUIDANCE
</TITLE>
<TITLE>
This guidance document is being distributed for comment purposes only.
</TITLE>
<TEXT>
Comments and suggestions regarding this draft document should be submitted within 75 days of publication in the Federal Register of the notice announcing the availability of the draft guidance. Submit electronic comments to http://www.regulations.gov. Submit written comments to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. All comments should be identified with the docket number listed in the notice of availability that publishes in the Federal Register.
</TEXT>
<UNSPECIFIED>
   U.S. Department of Health and Human Services
           Food and Drug Administration
  Center for Drug Evaluation and Research (CDER)
Center for Biologics Evaluation and Research (CBER)
       Center for Veterinary Medicine (CVM)
                    June 2014
                    Procedural
</UNSPECIFIED>
<PAGE_BREAK>
